Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Avalara, Inc. Common Stock
Fortune Bay Corp
Trulieve Cannabis Corp
Virtus Stone Harbor Emerging Markets Income Fund Common Shares of Beneficial
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
159.26
-2.26 (-1.40%)
Official Closing Price
Updated: 4:10 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Advances in Cancer Care Are Moving Closer to Home
October 29, 2026
(BPT) - Key takeaways:
Via
Brandpoint
Should You Buy Royalty Pharma Stock Before Nov. 4?
↗
October 29, 2026
Don't expect earnings day to sustain the stock's recent rally.
Via
The Motley Fool
What Novartis (NVS) Said on Its Q3 Earnings Call
↗
October 27, 2026
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core...
Via
MarketBeat
Topics
ETFs
Earnings
Novartis (NVS) Q3 2026 Earnings Call Transcript
↗
October 27, 2026
Priority brands offset generic erosion as margin expands and pipeline advances.
Via
The Motley Fool
Topics
Earnings
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile
↗
September 26, 2026
Via
Chartmill
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
↗
October 27, 2026
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker fell short.
Via
Investor's Business Daily
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
↗
October 23, 2026
Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion...
Via
MarketBeat
Topics
ETFs
If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid
↗
October 22, 2026
A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Economy
Where You Live Shouldn't Limit Your Cancer Care
October 20, 2026
(BPT) - Key takeaways:
Via
Brandpoint
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
↗
October 01, 2026
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.
Via
The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
September 29, 2026
DATELINE]As longevity research moves from animal models into human trials, investors are asking a sharper question: what is science, and...
Via
Newsfile
Leaders Face Stark Warning from Silicon Valley Veteran – The Old Way of Working is Dead
September 25, 2026
Via
Get News
Topics
Artificial Intelligence
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
↗
September 17, 2026
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
Via
The Motley Fool
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
↗
September 16, 2026
The pharmaceutical giant's track record in past bear markets is fairly impressive.
Via
The Motley Fool
Topics
Economy
Intellectual Property
Stocks
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
↗
September 16, 2026
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
Via
Investor's Business Daily
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
↗
September 15, 2026
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Via
The Motley Fool
Topics
ETFs
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
↗
September 14, 2026
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Via
The Motley Fool
Amgen Drops 10% on a Trial It Didn't Even Run
↗
September 11, 2026
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Via
MarketBeat
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
↗
September 11, 2026
Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.
Via
Benzinga
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
2025 R&D Spending And Intensity Benchmarks
September 09, 2026
Via
PRLog
Topics
Supply Chain
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons
↗
September 08, 2026
Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.
Via
The Motley Fool
Topics
Artificial Intelligence
Stocks
World Trade
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From
BioMedWire
Via
GlobeNewswire
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
↗
September 08, 2026
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
Via
Benzinga
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
↗
September 08, 2026
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
